1. Home
  2. CRT vs CALC Comparison

CRT vs CALC Comparison

Compare CRT & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cross Timbers Royalty Trust

CRT

Cross Timbers Royalty Trust

HOLD

Current Price

$8.61

Market Cap

42.5M

Sector

Energy

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$4.37

Market Cap

45.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRT
CALC
Founded
1991
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.5M
45.4M
IPO Year
1992
N/A

Fundamental Metrics

Financial Performance
Metric
CRT
CALC
Price
$8.61
$4.37
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
37.0K
97.0K
Earning Date
01-01-0001
11-12-2025
Dividend Yield
8.61%
N/A
EPS Growth
N/A
N/A
EPS
0.74
N/A
Revenue
$5,621,913.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.07
$1.42
52 Week High
$13.31
$4.82

Technical Indicators

Market Signals
Indicator
CRT
CALC
Relative Strength Index (RSI) 56.23 66.09
Support Level $8.29 $3.65
Resistance Level $8.99 $4.82
Average True Range (ATR) 0.20 0.38
MACD -0.06 0.10
Stochastic Oscillator 41.82 75.48

Price Performance

Historical Comparison
CRT
CALC

About CRT Cross Timbers Royalty Trust

Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: